Login / Signup

Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.

Vikas KumarMahfoozur RahmanPrashant GahtoriFahad A Al-AbbasiFiroz AnwarHyung Sik Kim
Published in: Expert opinion on drug delivery (2020)
Remarkable outcomes have recently been observed for the therapeutic efficacy of nanocarriers with respect to a specific drug target against the treatment of HCC by existing under trial drugs.
Keyphrases
  • cancer therapy
  • drug delivery
  • clinical trial
  • phase iii
  • phase ii
  • adipose tissue
  • skeletal muscle
  • insulin resistance
  • open label
  • weight loss